Veracyte

^{Priced, Nasdaq: VCYT}

Sells molecular diagnostic tests for thyroid cancer to reduce unnecessary surgeries.

Industry: Health Care

First Day Return: +1.9%

VCYT

Sells molecular diagnostic tests for thyroid cancer to reduce unnecessary surgeries.

IPO News for Veracyte

Cardiovascular disease diagnostic company CardioDx revives IPO plans; updates financials and changes underwriters 04/28/14
US IPO Recap: 2013 passes 2012 in proceeds raised 11/04/13
Veracyte prices upsized IPO at $13, the low end of the range 10/30/13

IPO Data
IPO Date	10/29/2013
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$65
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.veracyte.com
Headquarters	San Francisco, CA, United States
Founded	2006
Employees at IPO	107

IPO News for Veracyte

Veracyte (VCYT) Performance